Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare ...( Live Web Cast Scheduled for Ma...),Health

Live Web Cast Scheduled for May 19 at 10:15 a.m. Eastern Time

VANCOUVER, May 16 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday May 19th at 10:15 a.m. EDT.

A live web cast of the presentation will be available on the Company's Web site at http://www.responsebio.com/newsroom_events_calendar_corporate.asp?menu=1&su bmenu=3 and replays will be available for 14 days starting approximately three hours after the initial presentation.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests. In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 20
'/>"/>